CORXEL and LENZ Therapeutics announce positive topline data from phase 3 presbyopia trial of LNZ100 in China
74% of participants dosed with LNZ100 achieved 3 or more lines of improvement 3 hours post-treatment.
74% of participants dosed with LNZ100 achieved 3 or more lines of improvement 3 hours post-treatment.
OCT-based AI analysis brings changes in GA and therapeutic responses into sharp focus.
In this video, Dr. Rupin Parikh demonstrates how he used the power brow technique to improve significant brow ptosis in a 70-year-old patient with a…
We speak with Elad Serfaty, Chief Executive Officer of OrCam Technologies, about assistive technology for patients with low vision
CHICAGO — In this Healio Video Perspective from the AAO meeting, Zeba A. Syed, MD, discusses results of a study conducted at Wills Eye Hospital…
After speaking with team ophthalmologists and experts in eye protection, performance vision, and ocular trauma care, we have compiled a list of tips for young…
Primary and pre-op care can help millions of young patients with dry eye disease (DED), says Melissa Barnett, Director of Optometry at University of California,…
The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers.
Inherited retinal degenerations (IRDs) are a leading cause of blindness among the population of young people in the developed world. Approximately half of IRDs initially…
This study assesses the diagnostic efficacy of offline Medios Artificial Intelligence (AI) glaucoma software in a primary eye care setting, using nonmydriatic fundus images from…
Ophthalmologist-approved facts about colorful contacts, halloween, and cosplay costume eye safety.